An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number

BACKGROUND: First-line treatment with epidermal growth factor receptor (EGFR) inhibitors in NSCLC is effective in patients with activating EGFR mutations. The activity of erlotinib in patients harboring high EGFR gene copy number has been considered debatable. PATIENTS AND METHODS: A multicenter, op...

Descripción completa

Detalles Bibliográficos
Autores principales: Szutowicz-Zielinska, Ewa, Konopa, Krzysztof, Kowalczyk, Anna, Suszko-Kazarnowicz, Malgorzata, Duchnowska, Renata, Szczesna, Aleksandra, Ratajska, Magdalena, Sowa, Aleksander, Limon, Janusz, Biernat, Wojciech, Burzykowski, Tomasz, Jassem, Jacek, Dziadziuszko, Rafal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370039/
https://www.ncbi.nlm.nih.gov/pubmed/27924059
http://dx.doi.org/10.18632/oncotarget.13793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370039/
https://www.ncbi.nlm.nih.gov/pubmed/27924059
http://dx.doi.org/10.18632/oncotarget.13793

Ejemplares similares